| Autor: |
Débora Cerqueira Calderaro, Valéria Valim, Gilda Aparecida Ferreira, Ketty Lysie Libardi Lira Machado, Priscila Dias Cardoso Ribeiro, Sandra Lúcia Euzébio Ribeiro, Natalia Sarzi Sartori, Rodrigo Poubel Vieira de Rezende, Ana Karla Guedes de Melo, Vitor Alves Cruz, Adah Sophia Rodrigues Vieira, Adriana Maria Kakehasi, Aline Teixeira de Landa, Ana Paula Neves Burian, Flávia Maria Matos Melo Campos Peixoto, Camila Maria Paiva França Telles, Rafaela Cavalheiro do Espírito Santo, Katia Lino Baptista, Yasmin Gurtler Pinheiro de Oliveira, Vanessa de Oliveira Magalhães, Raquel Lima de Lima, Erika Biegelmeyer, Pietra Zava Lorencini, Andréa Teixeira-Carvalho, Edgard Torres dos Reis-Neto, Emília Inoue Sato, Marcelo de Medeiros Pinheiro, Odirlei André Monticielo, Viviane Angelina de Souza, Ricardo Machado Xavier, Gecilmara Salviato Pileggi |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Vaccines, Vol 12, Iss 9, p 1031 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2076-393X |
| DOI: |
10.3390/vaccines12091031 |
| Popis: |
Breakthrough COVID-19 (occurring in fully vaccinated people) has been described. Data on its characteristics among immune-mediated rheumatic disease (IMRD) patients are scarce. This study describes breakthrough COVID-19 occurring in IMRD patients participating in the SAFER-study, a Brazilian multicentric cohort evaluating the safety, effectiveness, and immunogenicity of SARS-CoV-2 vaccines in patients with autoimmune diseases. A descriptive analysis of the population and a binary logistic regression model were performed to evaluate the predictors of COVID-19-related hospitalization. A p-value < 0.05 was significant. The included 160 patients were predominantly females (83.1%), with a mean (SD) age of 40.23 (13.19) years. The patients received two (19%), three (70%), or four (11%) vaccine doses. The initial two-dose series was mainly with ChAdOx1 (Oxford/AstraZeneca) (58%) or BBIBP-CorV (Sinopharm-Beijing) (34%). The first booster (n = 150) was with BNT162b2 (BioNtech/Fosun Pharma/Pfizer) (63%) or ChAdOx1 (29%). The second booster (n = 112) was with BNT162b2 (40%) or ChAdOx1 (26%). The COVID-19 hospitalization rate was 17.5%. IMRD moderate/high activity (OR: 5.84; CI: 1.9–18.5; p = 0.002) and treatment with corticosteroids (OR: 2.94; CI: 1.02–8.49; p = 0.0043) were associated with higher odds of hospitalization, while increasing the number of vaccine doses was protective (OR: 0.37; CI: 0.15–0.9; p = 0.032). These findings, along with previous reassuring results about the safety of the COVID-19 vaccines, argue in favor of booster vaccination in IMRD patients. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
